Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours

Endocrine-Related Cancer

Volumn 11, Issue 3, 2004, Pages 553-561

  Zuetenhorst, J M ^a   Valdes Olmos, R A ^a   Muller, M ^a   Hoefnagel, C A ^a   Taal, B G ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 5 HYDROXYINDOLEACETIC ACID; PARACETAMOL; RECOMBINANT ALPHA2A INTERFERON; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PAIN; CANCER SCINTISCANNING; CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DRUG UPTAKE; FATIGUE; FEMALE; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT; HUMAN; HYPERTENSION; IMMUNOTHERAPY; LIVER METASTASIS; MALE; METASTASIS; NAUSEA; NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RATING SCALE; SCINTIGRAPHY; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY EXCRETION; VOMITING;

3-IODOBENZYLGUANIDINE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOID TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; INTERFERON ALFA-2B; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 4944246041     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00810     Document Type: Article

References (29)

1. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF & Burroughs AK 1998 Carcinoid tumour. Lancet 352 799-805.
2. Detjen KM, Welzel M, Farwig K, Brembeck FH, Kaiser A, Riecken EO, Wiedenmann B & Rosewicz S 2000 Molecular mechanism of Interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology 118 735-748.
3. Eissele R, Anlauf M, Schafer MK, Eiden LE, Arnold R & Weihe E 1999 Expression of vesicular monoamine transporters in endocrine hyperplasia and endocrine tumors of the oxyntic stomach. Digestion 60 428-439.
4. Geerlings SW, Beekman AT, Deeg DJ & Van Tilburg W 2000 Physical health and the onset and persistence of depression in older adults: an eight-wave prospective community-based study. Psychological Medicine 30 369-380.
5. Harris AG & Redfern JS 1995 Octreotide treatment of carcinoid syndrome: analysis of published dose-titration data. Alimentary Pharmacology and Therapeutics 9 387-394.
6. Hoefnagel CA 1991 Radionuclide therapy revisited. European Journal of Nuclear Medicine 18 408-431.
7. 131I-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG. Nuclear Medicine Communications 21 755-761.
8. Hou C, Chuang WL, Yu ML, Dai CY, Chen SC, Lin ZY, Hsieh MY, Wang LY, Tsai JF & Chang WY 2000 Incidence and associated factors of neutralizing anti-interferon antibodies among chronic hepatitis C patients treated with interferon in Taiwan. Scandinavian Journal of Gastroenterology 35 1288-1293.
9. Itri LM, Sherman MI, Palleroni AV, Evans LM, Tran LL, Campion M & Chizzonite R 1989 Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a. Journal of Interferon Research 9 (Suppl 1) S9-S15.
10. Kolby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wangberg B, Ahlman H, Forssell-Aronsson E & Nilsson O 2003 Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. British Journal of Cancer 89 1383-1388.
11. Kuin A, Smets L, Volk T, Paans A, Adams G, Atema A, Jahde E, Maas A, Rajewsky MF & Visser G 1994 Reduction of intratumoral pH by the mitochondrial inhibitor m-iodobenzylguanidine and moderate hyperglycemia. Cancer Research 54 3785-3792.
12. Langendijk JA, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Lamers RJ, Slotman BJ & Wouters EF 2001 Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. Journal of Clinical Oncology 19 2123-2133.
13. Larsson G, Sjoden PO, Oberg K, Eriksson B & von Essen L 2001 Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours. Acta Oncologica 40 825-831.
14. Moertel CG, Rubin J & Kvols LK 1989 Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. Journal of Clinical Oncology 7 865-868.
15. Montaldo PG, Carbone R, Ponzoni M & Cornaglia-Ferraris P 1992 γ-Interferon increases metaiodobenzylguanidine incorporation and retention in human neuroblastoma cells. Cancer Research 52 4960-4964.
16. 131)I-mIBG]. Clinical Endocrinology 55 47-60.
17. Oberg K 1992 The action of interferon alpha on human carcinoid tumours. Seminars in Cancer Biology 3 35-41.
18. Oberg K 1994 Treatment of neuroendocrine tumors. Cancer Treatment Reviews 20 331-355.
19. Oberg K & Alm G 1997 The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors. Biotherapy 10 1-5.
20. Oberg K, Eriksson B & Janson ET 1994 The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors. Annals of the New York Academy of Sciences 33 471-478.
21. 131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. European Journal of Surgical Oncology 27 404-408.
22. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML & Taal BG 2001 Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Annals of Oncology 12 1295-1300.
23. Radloff LS 1977 The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement 1 385-401.
24. Sarna L, Padilla G, Holmes C, Tashkin D, Brecht ML & Evangelista L 2002 Quality of life of long-term survivors of non-small-cell lung cancer. Journal of Clinical Oncology 20 2920-2929.
25. Schellekens H, Ryff JC & van der Meide PH 1997 Assays for antibodies to human interferon-alpha: the need for standardization. Journal of Interferon and Cytokine Research 17 (Suppl 1) S5-S8.
26. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H & Beijnen JH 1996 Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. Journal of Clinical Oncology 14 1829-1838.
27. 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Annals of Oncology 11 1437-1443.
28. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Valimaki MJ, Renstrup J, de Vries EG & Oberg KE 1999 Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. Journal of Clinical Oncology 17 1111-1117.
29. 131I- labelled MIBG and the combination. European Journal of Gastroenterology and Hepatology 11 1157-1164.